— Shares of Kodiak Sciences rose 9.4% after J.P. Morgan initiated coverage of the stock with an overweight rating.
The analyst cited positive development data from a new drug that could be used to treat multiple eye diseases that can cause vision loss as a reason for confidence in the stock. J.P. Morgan also gave a target price of $82 per share, a 24% premium from where shares closed on Monday.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Stocks making the biggest moves midday: Boeing, Tesla, CarMax, Apache & moreCheck out the companies making headlines in midday trading.
La source: CNBC - 🏆 12. / 72 Lire la suite »
Former Uber CEO Travis Kalanick leaving the company's board of directorsUber says that Travis Kalanick, its former CEO, will step down from the company’s board of directors effective Dec. 31. Add it to the list! QAnon
La source: NBCNews - 🏆 10. / 86 Lire la suite »
Former Uber CEO Kalanick to resign from company's boardNew York (AP) — Former Uber CEO Travis Kalanick will resign from the board next week, effectively severing ties with the ride-hailing company he co-founded a decade ago. Uber turbocharged... I use Lyft and couldn't be happier about it. Uber is a really shitty company with an even worse culture. Why is it the liberal media all run the same articles only a few mins apart? After he cashing out his shares of the company. He will be laughing all the way to the bank. 😉😂
La source: AP - 🏆 728. / 51 Lire la suite »
Travis Kalanick cuts last ties to Uber, will resign from company's boardThe departure does not come as a surprise as Kalanick has sold more than more than 90% of his shares -- worth about $2.5 billion. They're still a deeply shitty company.
La source: latimes - 🏆 11. / 82 Lire la suite »